# Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

Study · id `cardio:ct-nct05968430` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05968430](<https://clinicaltrials.gov/study/NCT05968430>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05968430

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1076 participants.

## Technical summary

Registry record NCT05968430. Non-randomized; no masking; primary purpose treatment. Start 2023-07-14 (actual); primary completion 2025-12-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1076 participants (enrolled count; ClinicalTrials.gov record NCT05968430, source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)
- Started: 2023-07-14 (actual) (ClinicalTrials.gov record NCT05968430, source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2025-12-30 (actual) (ClinicalTrials.gov record NCT05968430, source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)
- Completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT05968430, source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Australia; Bulgaria; Canada; France; Germany; Italy; Netherlands; Poland; Puerto Rico; Romania; Spain; United Kingdom (ClinicalTrials.gov record NCT05968430, source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05968430-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
- Condition: Hypertension
- Intervention (Drug): lorundrostat
- Intervention (Drug): Placebo
- Lead sponsor: Mineralys Therapeutics Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Mineralys Therapeutics Inc. (`cardio:org-mineralys-therapeutics-inc`)

## Provenance

Content hash: 01fbdc88ec17842882d10b15ffe1c77f8bf79d3809803220bb31abd25bf86f42
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
